Vivus Reveals Plans To Curb Costs As Qsymia Sales Lag
This article was originally published in The Pink Sheet Daily
Executive Summary
The company’s vague corporate update includes plans to focus the Qsymia sales team on the most productive areas and potential cost-saving measures for a planned cardiovascular outcomes trial.